Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.

Lisa Graille-AvyClemence BoutiereCamille RigolletMarine Perriguey Audrey Rico Sarah Demortiere Pierre Durozard Frederic Hilezian Frederic VelyPierre Bertault-PeresJean Pelletier Sandra Vukusic Bertrand Audoin

Published in: Neurology(R) neuroimmunology & neuroinflammation (2024)

For patients switching from FING to RTX/OCR, the risk of disease reactivation within the first 6 months of treatment was increased as compared with patients with other DMT or no previous DMT only when the washout period exceeded 26 days. Neither FING nor other previous DMT reduced the effectiveness of RTX/OCR beyond the first 6 months of treatment.

Keyphrases

randomized controlled trial
ejection fraction
prognostic factors
chronic kidney disease
smoking cessation
hodgkin lymphoma